Sino Biopharmaceutical (SBMFF)
(Delayed Data from OTC)
$0.38 USD
0.00 (0.00%)
Updated Aug 19, 2024 12:12 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Income Statements
Fiscal Year end for Sino Biopharmaceutical falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | 3,426 | 3,507 |
Cost Of Goods | NA | NA | NA | 751 | 713 |
Gross Profit | NA | NA | NA | 2,676 | 2,794 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 0 | 0 | 1,902 | 1,969 |
Income After Depreciation & Amortization | 0 | 0 | 0 | 774 | 825 |
Non-Operating Income | NA | NA | NA | 0 | 16 |
Interest Expense | NA | NA | NA | 47 | 33 |
Pretax Income | NA | NA | NA | 726 | 808 |
Income Taxes | NA | NA | NA | 97 | 129 |
Minority Interest | NA | NA | NA | 227 | 288 |
Investment Gains/Losses | NA | NA | NA | 0 | 0 |
Other Income/Charges | NA | NA | NA | 0 | 0 |
Income From Cont. Operations | NA | NA | NA | 629 | 679 |
Extras & Discontinued Operations | NA | NA | NA | 0 | 0 |
Net Income (GAAP) | NA | NA | NA | 402 | 392 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | 0 | 0 | 1,003 | 1,037 |
Depreciation & Amortization (Cash Flow) | NA | NA | NA | 229 | 212 |
Income After Depreciation & Amortization | 0 | 0 | 0 | 774 | 825 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | 18,799.77 | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | 0.02 | NA |
Diluted Net EPS (GAAP) | NA | NA | NA | 0.02 | 0.02 |
Fiscal Year end for Sino Biopharmaceutical falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | NA |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | NA | NA | NA |
Extras & Discontinued Operations | NA | NA | NA | NA | NA |
Net Income (GAAP) | NA | NA | NA | NA | NA |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | NA |